In Kathmandu, a municipal health campaign quietly examined nearly three thousand women for a virus most of them had no reason to suspect — and found ninety carrying it, the majority infected with strains that Nepal's vaccine was never designed to stop. The discovery does not indict the vaccine so much as it illuminates the distance between what immunization can promise and what a population actually faces. Cervical cancer claims an estimated four Nepali women every day, most of them never screened until symptoms have already narrowed their options. This campaign, modest in scale, asks a questi
Kathmandu screening reveals HPV infections beyond vaccine coverage in 90 women
11 women diagnosed with precancerous cervical lesions; cervical cancer kills an estimated 4 Nepali women daily, with hundreds diagnosed annually.
Many women who believe themselves healthy are living with cancer-causing viruses
Mark
Why does it matter that 65 of the 90 women carried HPV types the vaccine doesn't cover?
Mimi
Because those types can still cause cancer. The vaccine protects against the two most dangerous strains, but it leaves women vulnerable to a dozen other high-risk types. You can be vaccinated and still get infected.
Mark
So the vaccine isn't a failure—it's incomplete?
Mimi
Exactly. It's doing what it was designed to do. But the screening revealed that Nepal's women are encountering HPV types the vaccine never addresses. That's a gap in protection.
Mark
What's the real danger here—the infections themselves, or the fact that these women didn't know they had them?
Mimi
Both. The infections themselves can become cancer. But the fact that they were asymptomatic is actually the hopeful part. These women were caught before symptoms appeared, before the disease progressed. That's when treatment works.
Mark
If four women die of cervical cancer every day in Nepal, why isn't screening already everywhere?
Mimi
Resources, mostly. This screening took months and required specialized equipment and trained staff. The health department had limited testing kits. Most local facilities don't have the capacity to do what Kathmandu just did.
Mark
What happens to the eleven women with precancerous lesions now?
Mimi
They're being monitored and treated. The point is they caught it early enough that cancer hasn't developed yet. If screening had come later, or not at all, some of them might have become part of that daily death toll.
Der Puls
- Ninety women were silently carrying cancer-linked viruses — none had symptoms, none suspected a thing until a city-run screening intervened.
- Sixty-five of those infections involved HPV strains entirely outside the reach of Nepal's current vaccine, exposing a structural blind spot in the national immunization strategy.
- Eleven women were diagnosed with precancerous cervical lesions — four of them high-grade — meaning the screening caught real danger before it could become irreversible.
- Two women discovered through the campaign's breast screening component are now in active cancer treatment, lives redirected by a single health visit.
- Experts and officials are pressing local governments to embed routine cancer screening into community health facilities, arguing that a one-city campaign cannot carry a national burden.
In Kathmandu, a municipal health campaign quietly examined nearly three thousand women for a virus most of them had no reason to suspect — and found ninety carrying it, the majority infected with strains that Nepal's vaccine was never designed to stop. The discovery does not indict the vaccine so much as it illuminates the distance between what immunization can promise and what a population actually faces. Cervical cancer claims an estimated four Nepali women every day, most of them never screened until symptoms have already narrowed their options. This campaign, modest in scale, asks a question that health systems everywhere must eventually answer: when prevention has limits, how far does the obligation to look extend?
Ninety women in Kathmandu learned they were carrying human papillomavirus infections they had no reason to suspect. None showed symptoms. The discovery came through a cervical cancer screening campaign run by the Kathmandu Metropolitan City health department between late March and early May, which examined nearly three thousand women.
Of those screened, 2,779 underwent HPV DNA testing. A subset of 1,329 were tested specifically for types 16 and 18 — the two strains targeted by Nepal's routine immunization program for ten-year-old girls, which together account for roughly seventy percent of cervical cancers worldwide. But the results revealed something vaccination alone cannot resolve: of the 90 women who tested positive, only 25 carried types 16 or 18. The remaining 65 were infected with other high-risk strains the current vaccine does not cover.
All 90 HPV-positive women underwent colposcopy for closer examination. Twenty-four received cervical biopsies, and eleven were diagnosed with precancerous lesions — four of them high-grade, carrying meaningful risk of progressing to cancer without treatment. The screening also extended to breast health: two women identified through mammography tested positive for breast cancer and are now receiving treatment.
Chandra Bhatta, who oversees the city's screening program, noted that many women living with cancer-causing viruses consider themselves perfectly healthy. Dr. Ujjwal Chalise of Bhaktapur Cancer Hospital pointed to the deeper pattern: most cancer patients in Nepal arrive for care only after symptoms appear, by which point the disease has often advanced. The eleven precancerous diagnoses represent the alternative — intervention before cancer takes hold.
Nepal's vaccine targets only two of the fourteen high-risk HPV types known to cause cervical and other cancers. The Kathmandu findings make plain that the population encounters a far wider range. Health officials are now calling for expanded screening access at local facilities across the country, and raising the question of whether the national vaccine strategy should broaden its scope to match the infections actually circulating.
Ninety women in Kathmandu discovered they were carrying human papillomavirus infections they didn't know they had. None showed symptoms. None had reason to suspect anything was wrong until the Kathmandu Metropolitan City's health department ran a cervical cancer screening campaign between late March and early May.
The screening examined nearly 3,000 women. Of those, 2,779 underwent HPV DNA testing to detect the virus's genetic material in cervical cells. A smaller subset—1,329 women—were tested specifically for HPV types 16 and 18, the two strains that Nepal's routine immunization program targets in 10-year-old girls. Those two types account for roughly 70 percent of cervical cancer cases worldwide. But the results revealed something the vaccine alone cannot address: the 90 women who tested positive included only 25 infected with types 16 or 18. The remaining 65 carried other HPV strains—types not covered by the current vaccination strategy.
Chandra Bhatta, who oversees the cervical cancer screening program for the city, explained the finding plainly: many women who believe themselves healthy are actually living with cancer-causing viruses. The human papillomavirus spreads through skin-to-skin contact and is the leading cause of cervical cancer, the second-most common cancer in the developing world. In Nepal, cervical cancer kills an estimated four women every day, though the exact number of cases remains unknown. Hundreds are diagnosed annually.
All 90 HPV-positive women underwent colposcopy, a procedure in which a doctor uses a magnified instrument to examine the cervix, vagina, and vulva closely. The follow-up work was extensive: six women required removal of uterine polyps, and 24 underwent cervical biopsy. Eleven women received a diagnosis of cervical intraepithelial neoplasia—precancerous changes in the cells lining the cervix. Four of those cases were high-grade lesions, meaning they carry significant risk of developing into actual cancer if left untreated. Seven were low-grade. The condition itself is not cancer, but it is a warning.
The screening also extended beyond cervical cancer. The health department examined the breasts of 2,961 women and performed mammography on 411 of them. Four women underwent breast biopsy, and two tested positive for breast cancer. Both are now in treatment.
The findings expose a gap in Nepal's public health approach. The country's routine immunization program provides a single dose of HPV vaccine to all 10-year-old girls, targeting only types 16 and 18. But human papillomavirus has more than 200 known types. Around 40 infect the genital tract. Fourteen are classified as high-risk because they can cause cervical and other cancers. The low-risk types typically cause genital warts or produce no symptoms at all. The Kathmandu screening demonstrates that women in Nepal encounter a diverse range of HPV types, many of which the current vaccine does not address.
Dr. Ujjwal Chalise, executive director of Bhaktapur Cancer Hospital, pointed to a deeper problem: most cancer patients in Nepal seek treatment only after symptoms appear. Early-stage disease often produces no warning signs. By the time symptoms emerge, the disease has often progressed beyond the point where treatment works well. The eleven women diagnosed with precancerous lesions in this screening represent a different outcome—detection before cancer develops, when intervention can prevent progression.
Health officials are calling for local governments to ensure that basic cancer screening services are available at local health facilities. Early detection, experts say, markedly improves treatment outcomes. The question now is whether Nepal's health system can expand screening access beyond a single metropolitan campaign, and whether vaccine strategy should evolve to address the broader range of HPV types circulating in the population.
Bemerkenswerte Zitate
Our findings show that many women, who believe they are healthy may be living with various forms of cancer and infected with cancer-causing viruses.— Chandra Bhatta, focal person of the cervical cancer screening programme
Most cancer patients in Nepal seek treatment only after symptoms start to emerge. By the time they do, it is often too late, resulting in poor treatment outcomes.— Dr. Ujjwal Chalise, executive director at Bhaktapur Cancer Hospital
Möchten Sie die ganze Geschichte?
Das Original lesen bei Asia News Network ↗
Health & Medicine